CO
COYA.US Coya Therapeutics, Inc. Common Stock
- Market cap
- USD 73.4M
- P/E
- -
- P/B
- 2.29x
- ROE
- -97.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is COYA.US undervalued?
Graham numberThe Graham number of Coya Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Coya Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Coya Therapeutics, Inc. Common Stock yet.
Coya Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector fu…
Full company profileCoya Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Coya Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 6.00M | 3.55M | 7.95M | 972K |
| Gross Profit | - | -16.1K | -4.41M | 501K | -8.31M | 7.92M | 972K |
| Operating Income | -1.04M | -4.87M | -9.81M | -7.90M | -17.2M | -20.3M | -34.2M |
| EBITDA | 10.4K | -4.88M | -9.26M | -7.33M | -17.2M | -21.2M | -33.2M |
| Net Income | -1.10M | -4.89M | -12.2M | -7.99M | -14.9M | -21.2M | -32.6M |
| EPS | -0.42 | -0.74 | -1.23 | -0.79 | -0.98 | -1.27 | -1.39 |
| Balance Sheet | |||||||
| Total Assets | 8.75M | 4.79M | 8.40M | 41.3M | 44.3M | 50.0M | 39.3M |
| Total Liabilities | 447K | 1.15M | 16.8M | 5.63M | 4.77M | 6.92M | 5.75M |
| Shareholders' Equity | 8.30M | 3.64M | -8.39M | 35.6M | 39.6M | 43.0M | 33.6M |
| Cash & Short-term Investments | 8.72M | 4.34M | 5.93M | 32.6M | 38.3M | 46.8M | 35.8M |
| Total Debt | - | - | 13.0M | - | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -391K | -3.90M | -7.24M | -11.2M | -10.3M | -10.7M | -27.8M |
| Capital Expenditure | 4.00 | 137K | 4.00 | 1.00 | 0.00 | 0.00 | 2.36M |
| Free Cash Flow | -391K | -4.04M | -7.24M | -11.2M | -10.3M | -10.7M | -26.6M |
| Ratios | |||||||
| ROE | -13.2% | -134.3% | - | -22.4% | -37.6% | -49.3% | -97.2% |
| ROA | -12.6% | -102.1% | -145.8% | -19.4% | -33.6% | -42.5% | -83.0% |
| Net Profit Margin | - | - | - | -133.1% | -418.7% | -267.1% | -3,355.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Coya Therapeutics, Inc. Common Stock dividends
Coya Therapeutics, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Who owns Coya Therapeutics, Inc. Common Stock
- Insiders 14.69%
- Institutions 32.89%
- Public & others 52.42%
- Shares outstanding 23.5M
- Free float 17.5M
Top funds holding COYA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 601K | 2.56% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 95.2K | 0.41% | -12.88% | Sep 2026 |
| Dimensional US Small Cap ETF | 75.6K | 0.32% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 59.8K | 0.26% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 38.5K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 32.4K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 31.1K | 0.13% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 13.1K | 0.06% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 11.2K | 0.05% | 0.00% | Oct 2026 |
| Vanguard Balanced Index Inv | 10.9K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 10.2K | 0.04% | 0.00% | Sep 2026 |
| Schwab Total Stock Market Index | 10.0K | 0.04% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 8.30K | 0.04% | +136.71% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 6.90K | 0.03% | -53.69% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 5.88K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Vector Equity ETF | 4.79K | 0.02% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 4.56K | 0.02% | +165.89% | Sep 2026 |
| Dimensional International Core Eq Acc | 4.19K | 0.02% | 0.00% | Sep 2026 |
| Dimensional World Equity GBP Acc | 3.80K | 0.02% | -0.21% | Sep 2026 |
| 1290 VT Micro Cap K | 3.66K | 0.02% | -17.45% | Sep 2026 |
Top institutions holding COYA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 842K | 3.59% | -0.32% | Jun 2026 |
| Alyeska Investment Group, L.P. | 800K | 3.41% | 0.00% | Jun 2026 |
| AIGH Capital Management, LLC | 632K | 2.69% | -35.22% | Jun 2026 |
| CM Management, LLC | 400K | 1.71% | +6.67% | Jun 2026 |
| Private Management Group Inc | 384K | 1.64% | +4.10% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 250K | 1.06% | +10.63% | Jun 2026 |
| Geode Capital Management, LLC | 228K | 0.97% | -2.21% | Jun 2026 |
| Renaissance Technologies Corp | 193K | 0.82% | +85.63% | Jun 2026 |
| Prosight Management, LP | 170K | 0.72% | -59.56% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 169K | 0.72% | +8.68% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 130K | 0.55% | -7.39% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 111K | 0.47% | +146.69% | Jun 2026 |
| BlackRock Inc | 102K | 0.44% | +23.73% | Jun 2026 |
| Springbok Capital Management, LLC | 101K | 0.43% | 0.00% | Jun 2026 |
| JBF Capital, Inc. | 100K | 0.43% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 93.4K | 0.40% | +597.54% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 82.1K | 0.35% | -4.19% | Jun 2026 |
| State Street Corp | 79.8K | 0.34% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 61.0K | 0.26% | +55.17% | Jun 2026 |
| Northern Trust Corp | 45.1K | 0.19% | +11.51% | Jun 2026 |
Coya Therapeutics, Inc. Common Stock company profile
- Company name
- Coya Therapeutics, Inc. Common Stock
- Ticker
- COYA.US
- Exchange
- USA Stocks
- Listed since
- Dec 29, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 5850 San Felipe St., Houston, TX, United States, 77057
- Phone
- 800 587 8170
- Website
- coyatherapeutics.com
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Coya Therapeutics, Inc. Common Stock management
6- Dr. Arun Swaminathan Ph.D.CEO & Director · born 1969
- Dr. Fred Grossman D.O., FAPAPresident & Chief Medical Officer · born 1959
- Mr. David S. Snyder M.B.A.CFO & COO · born 1960
- Mr. Aaron Thome Ph.D.Head of Neuroinflammation Platform
- Dr. Michelle Frazier Ph.D.Senior Vice President of Regulatory
- Ms. Karen King M.S.Senior VP of Program Management & Clinical Operations